4507.T | Ticker Profile - Titan Protect

4507.T

Shionogi & Co., Ltd.

Healthcare · ·

$2,844.50

Data: 2026-05-28

✓ ETHICAL PASS

MODERATE MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$16.0B

Total market value of the company

Trailing P/E

12.44

Reasonably valued

Forward P/E

15.67

Based on estimated future earnings — lower means cheaper

Rev Growth

+32.8%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally.

Country: Japan Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

N/A

Core business does not involve prohibited activities

Debt Ratio

0.0%

Debt must be below 33% of total assets

Cash Ratio

0.0%

Interest-bearing cash below 33% of assets

Receivables

0.0%

Receivables below 49% of assets

Revenue Purity

0.0%

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$22.67

What our model estimates this business is worth per share

Margin of Safety

-12,446.0%

Trading above fair value — no margin of safety

Rating

Overall assessment combining ethics, valuation, and quality

Percentile

61.9th

Ranks in the top 38% of our 13,571 screened universe

Ethical Score

N/A

Valuation Score

61.0

Quality Score

52.5

Combined

43.3

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.704

Good returns relative to risk taken

Kelly Fraction

0.0556

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.883

Acceptable balance between returns and drawdown risk

Annual Return

16.9%

Historical annualised return based on price data

Max Drawdown

-19.2%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$1.51

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-18.6%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go